Form 4: Arbutus Biopharma CEO Reports Stock Transaction
Insider Transaction (Form 4)
Lindsay Androski, President and CEO and a Director of Arbutus Biopharma Corp, reported a transaction in 24,655 shares of common stock on October 1, 2026.
Summary
- Disposition to the issuer: disposed of 24,655 Common Shares at $5.00 ($123,275) on October 1, 2026; holds 47,682 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Lindsay Androski — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Disposition to the issuer | Common Shares | 24,655 | $5 | $123.3K | 47,682 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Disposition to the issuer (24,655 shares) |
Keywords
insider transaction, Form 4, ABUS, Arbutus Biopharma Corp, neutral, Lindsay Androski
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.